David W.  Gryska net worth and biography

David Gryska Biography and Net Worth

Mr. Gryska possesses decades of experience as a C-suite executive and director at a number of leading public biopharmaceutical companies. He most recently served as Executive Vice President and Chief Financial Officer of Incyte Corporation, a biopharmaceutical company (NASDAQ: INCY). Additionally, Mr. Gryska served as Chief Operating Officer of Myrexis, Inc., a biopharmaceutical company as well as Senior Vice President and Chief Financial Officer of Celgene Corporation, a former publicly traded biopharmaceutical company acquired by Bristol-Myers Squibb Company. Previously, Mr. Gryska served at Scios Inc., a former publicly traded biopharmaceutical company acquired by Johnson & Johnson, as Senior Vice President and Chief Financial Officer. Mr. Gryska also served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways Corporation, a former publicly traded medical device company acquired by Boston Scientific Corporation. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young LLP in California. Mr. Gryska currently serves on the board of directors of Forte Biosciences, Inc. (NASDAQ: FBRX).

He holds a Bachelor of Arts in Accounting and Finance from Loyola University and an M.B.A. from Golden Gate University.

What is David W. Gryska's net worth?

The estimated net worth of David W. Gryska is at least $301.04 thousand as of August 23rd, 2024. Mr. Gryska owns 17,351 shares of Definium Therapeutics stock worth more than $301,040 as of February 10th. This net worth evaluation does not reflect any other investments that Mr. Gryska may own. Learn More about David W. Gryska's net worth.

How do I contact David W. Gryska?

The corporate mailing address for Mr. Gryska and other Definium Therapeutics executives is One World Trade Center Suite 8500 New York, NY 10007 United States. Definium Therapeutics can also be reached via phone at 212 220 6633 and via email at [email protected]. Learn More on David W. Gryska's contact information.

Has David W. Gryska been buying or selling shares of Definium Therapeutics?

David W. Gryska has not been actively trading shares of Definium Therapeutics in the last ninety days. Most recently, on Friday, August 23rd, David W. Gryska bought 3,500 shares of Definium Therapeutics stock. The stock was acquired at an average cost of $5.98 per share, with a total value of $20,930.00. Following the completion of the transaction, the director now directly owns 17,351 shares of the company's stock, valued at $103,758.98. Learn More on David W. Gryska's trading history.

Who are Definium Therapeutics' active insiders?

Definium Therapeutics' insider roster includes Robert Barrow (Chief Executive Officer and Board Director), Schond Greenway (CFO), David Gryska (Director), Dan Karlin (Insider), Daniel Karlin (Insider), Carrie Liao (CAO), and Mark Sullivan (Insider). Learn More on Definium Therapeutics' active insiders.

Are insiders buying or selling shares of Definium Therapeutics?

During the last twelve months, insiders at the sold shares 12 times. They sold a total of 163,667 shares worth more than $1,515,041.22. The most recent insider tranaction occured on December, 26th when insider Daniel Karlin sold 5,600 shares worth more than $73,640.00. Insiders at Definium Therapeutics own 2.3% of the company. Learn More about insider trades at Definium Therapeutics.

Information on this page was last updated on 12/26/2025.

David W. Gryska Insider Trading History at Definium Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2024Buy3,500$5.98$20,930.0017,351View SEC Filing Icon  
See Full Table

David W. Gryska Buying and Selling Activity at Definium Therapeutics

This chart shows David W Gryska's buying and selling at Definium Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Definium Therapeutics Company Overview

Definium Therapeutics logo
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $17.35
Low: $16.55
High: $17.40

50 Day Range

MA: $14.38
Low: $11.94
High: $18.23

2 Week Range

Now: $17.35
Low: $4.70
High: $18.70

Volume

829,525 shs

Average Volume

1,992,820 shs

Market Capitalization

$1.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57